Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dance 501 Dose Response in T2DM
NCT04100473Phase 2Completed
- Sponsor
- Aerami Therapeutics
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Dance-501 in type 2 diabetes mellitus (T2DM), sponsored by Aerami Therapeutics. Started Apr 2018; status: completed.
02
Drugs
Dance-501
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04100473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100473.